Association of cardiac enzymes with morbidity and mortality of patients undergoing coronary endarterectomy surgery

Aghigh Heydari MD(1), Feridoun Sabzi MD(1), Atefeh Asadmobini MSc(1), Soudabeh Eskandari MSc(1,2)

Abstract

BACKGROUND: The relationship between cardiac enzyme release following coronary endarterectomy (CE) and morbidity and mortality is unclear. Therefore, the present study aimed to investigate the association of cardiac enzymes with morbidity and mortality of patients undergoing CE surgery.

METHODS: This was a single-center retrospective cohort study of 475 patients who had undergone off-pump coronary artery bypass graft (OPCABG). The patients were followed up for a mean of 72.99 ± 14.60 months.

RESULTS: Among 475 patients undergoing OPCABG, 39 (8.2%) were non-survivors. Non-survivors were younger and had a fewer ejection fraction (EF). Comorbidities were similar in survivors and non-survivors. The crude Cox regression analysis showed that creatine kinase-myocardial band (CK-MB) had a protective effect against mortality, but when adjusted with age, sex, diabetes mellitus (DM), hypertension (HTN), hyperlipidemia, smoking, family history, body mass index (BMI), left main disease (LMD), and EF, this effect disappeared. Troponin in crude and adjusted analysis did not have any significant effect.

CONCLUSION: There is no association between CK-MB and troponin and mortality in patients undergoing coronary artery bypass graft (CABG).

Keywords: Biomarkers; Coronary Artery Bypass, Off-Pump; Creatine Kinase, MB Form; Endarterectomy; Troponin

Date of submission: 02 Dec. 2019, Date of acceptance: 10 May 2020

Introduction

Coronary artery disease (CAD) is one of the major causes of death in the world, with 4.5 million deaths occurring in developing countries. CAD treatment with coronary artery bypass graft (CABG) alone does not provide satisfactory results. To achieve better results in diffuse CAD, surgical techniques such as coronary endarterectomy (CE) can be used. Recently, surgeons are still unwilling to use CE in combination with CABG due to increase of mortality and myocardial infarction (MI) after surgery. On the other hand, researchers recently reported good and long-term perioperative outcomes from CABG/CE, with evidence of different outcomes and with respect to coronary arteries requiring endarterectomy.

MI in patients undergoing open-heart surgery is the main determinant of postoperative complications and mortality. The incidence of both peri- and postoperative MI was significantly higher in the CE patients, although significant heterogeneity exists on the postoperative MI outcome. Detection of MI after surgery which leads to death of myocytes is a challenging task. Elevations of the biochemical markers of myocardial damage, creatine kinase-myocardial band (CK-MB), and troponin are common after CABG surgery and have been associated with increased in-hospital and short-term mortality.

The relationship between increased postoperative concentration of troponin and how to cite this article: Heydari A, Sabzi F, Asadmobini A, Eskandari S. Association of cardiac enzymes with morbidity and mortality of patients undergoing coronary endarterectomy surgery. ARYA Atheroscler 2021; 17: 2085.

1- Cardiovascular Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Department of Biostatistics and Epidemiology, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Address for correspondence: Atefeh Asadmobini; Cardiovascular Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; Email: a.asadmobini@gmail.com

DOI: http://dx.doi.org/10.22122/arya.v17i0.2085
Published by Vespu Publications

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Association of cardiac enzymes with mortality

postoperative morbidity and mortality has been well established in recent studies.\textsuperscript{13,14}

The specific cardiac isoenzyme CK-MB is known as a susceptible indicator of cardiac muscle necrosis and it is important to measure its serum activity during postoperative CABG surgery.\textsuperscript{15} Other cardiac enzymes such as lactate dehydrogenase (LDH) and troponin are also valuable criteria for determining the cell death rate in the heart muscle.\textsuperscript{15} Several studies have shown that increased cardiac enzymes in the first 24 hours after CABG surgery are associated with worse prognosis.\textsuperscript{16} Recently, several studies have been performed on the relationship of cardiac enzymes with survival in CABG patients,\textsuperscript{2,3,4,5} but there is not any investigation on the changes in cardiac enzymes in patients undergoing CE. Therefore, the present study aimed to investigate the association of cardiac enzymes with morbidity and mortality of patients undergoing CE surgery.

Materials and Methods

Study type: This was a single-center retrospective cohort study on patients who underwent off-pump CABG (OPCABG) + CE in Imam Ali Hospital, Kermanshah, Iran. This study was approved by the Ethics Committee of Kermanshah University of Medical Sciences. The patients were divided into two groups, the survivor and the non-survivor groups and analyzed according to cardiac enzyme.

Sample: With census method, we reviewed the medical records of 659 patients who had been undergoing OPCABG between March 2011 and February 2012. After exclusion of patients who had other procedures in addition to OPCABG, such as valve repair or replacement and left ventricular (LV) aneurysm resection, 475 patients met our criteria. Of these 475 patients, 69 had CE in addition to OPCABG.

Follow-up: The endpoint was all-cause mortality, which was evaluated by telephone contact after discharge for a mean follow-up of 72.99 ± 14.60 months.

Surgical procedure: All patients were operated on with median sternotomy and using the standard technique of cardiopulmonary bypass (CPB) with off-pump technique, as previously described.\textsuperscript{18,19} Data collection: It was conducted through analysis of medical records with a standardized form, including preoperative variables, which consisted of the following: age, gender, body mass index (BMI), diabetes mellitus (DM), hypertension (HTN), hypercholesterolemia, smoking history, family history of CAD, LV ejection fraction (LVEF), previous MI, history of arrhythmia, angina, previous CABG, and left main CAD (LMCAD). Operative data included number of vessel diseases and postoperative variables were MI, arrhythmia, low cardiac output, bleeding, blood transfusion in the intensive care unit (ICU), total length of ICU stay, and hospital mortality.

Definitions: Bleeding was considered when patients needed re-operation. Hospital mortality was defined as death occurring before discharge from the hospital and death was classified as either cardiac or non-cardiac mortality. Arrhythmia refers to postoperative atrial fibrillation (AF) or flutter, heart blockage that requires a pacemaker, and ventricular arrhythmias.

Statistical analysis: Continuous variables were presented as mean ± standard deviation (SD) and categorical variables with absolute value and percentage. Chi-square test and Student’s t-test were used to compare the baseline characteristics between survivor and non-survivor patients.

A crude and adjusted Cox proportional hazards model was used to identify risk factors and protective factors relating to mortality. The results were expressed as hazard ratios (HR) with associated 95% confidence interval (CI). The results were considered to be statistically significant with a P-value of < 0.05. All analyses were performed by SPSS software (version 20, IBM Corporation, Armonk, NY, USA).

Results

The study population comprised of 475 patients with a mean age of 58.5 ± 9.5 years (range: 32 to 90 years). Distribution of demographic and clinical variables is listed in table 1. 406 patients (85.5%) underwent OPCABG and 69 (14.5%) underwent OPCABG + CE surgery. In this study, survival time was considered as the elapsed time from the time of surgery to death. The patients were followed up for a mean of 76.70 ± 0.16 months. In the OPCABG group, 32 (7.9%) patients and in the OPCABG + CE group, 7 (10.1%) patients died during the follow-up period. The long-term survival rate using nonparametric Kaplan-Meier method in OPCABG patients was 99.3% and 98.4% in OPCABG + CE patients. The risk ratio in OPCABG + CE patients was 1/2 times more than OPCABG. On the other words, CABG patients significantly had a higher survival time.

A crude and adjusted analysis was used to identify risk and protective factors relating to mortality.
Table 1. Descriptive statistics of the survivor and non-survivor patients

| Variable                  | Survivors (n = 436) | Non-survivors (n = 39) | Total     | P       |
|---------------------------|---------------------|------------------------|-----------|---------|
| Age (year)                |                     |                        |           |         |
| < 50                      | 92 (21.1)           | 3 (7.7)                | 95 (20.0) | 0.001   |
| 50-70                     | 297 (68.1)          | 24 (61.5)              | 321 (67.6) |         |
| > 70                      | 47 (10.8)           | 12 (30.8)              | 59 (12.4) |         |
| Gender                    |                     |                        |           |         |
| Men                       | 322 (73.9)          | 30 (76.9)              | 352 (74.1) | 0.840   |
| Women                     | 114 (26.1)          | 9 (23.1)               | 123 (25.9) |         |
| HTN                       | Yes                 | 195 (44.7)             | 21 (53.8) | 216 (45.5) | 0.310   |
| Hyperlipidemia            | Yes                 | 147 (33.7)             | 9 (23.1)  | 156 (32.8) | 0.210   |
| Diabetes                  | Yes                 | 117 (26.8)             | 10 (25.6) | 127 (26.7) > 0.999 |
| Smoking                   | Yes                 | 185 (42.4)             | 15 (38.5) | 200 (42.1) | 0.730   |
| Family history            | Yes                 | 128 (29.4)             | 7 (17.9)  | 135 (28.4) | 0.140   |
| Recent MI                 | Yes                 | 42 (9.6)               | 5 (12.8)  | 47 (9.9)  | 0.570   |
| LMD                       | Yes                 | 89 (20.4)              | 6 (15.4)  | 95 (20.0) | 0.530   |
| Bleeding after surgery    | Yes                 | 32 (7.3)               | 3 (7.7)   | 35 (7.4)  > 0.999 |
| < 18.5                    | 6 (1.4)             | 1 (2.6)                | 7 (1.5)   | 0.890   |
| 18.5-24.9                 | 97 (22.2)           | 8 (20.5)               | 105 (22.1) |         |
| BMI (kg/m²)               |                     |                        |           |         |
| < 30                      | 257 (58.9)          | 22 (56.4)              | 279 (58.7) |         |
| 30-40                     | 76 (17.4)           | 8 (20.5)               | 84 (17.7) | 0.002   |
| < 30                      | 63 (14.4)           | 14 (35.9)              | 77 (16.2) | 0.002   |
| 30-40                     | 85 (19.5)           | 9 (23.1)               | 94 (19.8) |         |
| EF (%)                    |                     |                        |           |         |
| < 30                      | 97 (22.2)           | 8 (20.5)               | 105 (22.1) |         |
| 30-40                     | 191 (43.8)          | 8 (20.5)               | 199 (41.9) |         |
| > 50                      | 29 (6.7)            | 3 (7.7)                | 32 (6.7)  | 0.840   |
| CAD (number of vessel)    |                     |                        |           |         |
| 2                        | 92 (21.1)           | 10 (25.6)              | 102 (21.5) |         |
| 3                        | 280 (64.2)          | 24 (61.5)              | 304 (64.0) |         |
| 4                        | 35 (8.0)            | 2 (5.1)                | 37 (7.8)  |         |
| Troponin (ng/ml)          |                     |                        |           |         |
| < 0.845                  | 26 (6.0)            | 4 (10.3)               | 30 (6.3)  | 0.290   |
| > 0.845                  | 410 (94.0)          | 35 (89.7)              | 445 (93.7) |         |
| CK-MB (IU/l)              |                     |                        |           |         |
| < 26.5                   | 176 (41.1)          | 19 (40.0)              | 195 (41.1) | 0.310   |
| > 26.5                   | 260 (58.9)          | 20 (60.0)              | 280 (58.9) |         |
| Type of surgery           |                     |                        |           |         |
| OPCABG                    | 374 (85.8)          | 32 (82.1)              | 406 (85.5) | 0.480   |
| OPCABG + CE               | 62 (14.2)           | 7 (17.9)               | 69 (14.5) |         |
| ICU stay (hour)           | 39.1 ± 24.4         | 42.2 ± 24.5            | 39.4 ± 24.4 | 0.470   |

Data are presented as mean ± standard deviation (SD) or number and percentage.

BMI: Body mass index; MI: Myocardial infarction; LMD: Left main disease; EF: Ejection fraction; CAD: Coronary artery disease; CK-MB: Creatine kinase-myocardial band; ICU: Intensive care unit; HTN: Hypertension.

The results of the crude and adjusted analyses, using the Cox proportional hazard model, are shown in table 2.

The crude Cox regression analysis showed that CK-MB had a protective effect against mortality, but when adjusted with age, sex, DM, HTN, hyperlipidemia, smoking, family history, BMI, left main disease (LMD), and EF, this effect disappeared. Troponin in crude and adjusted analysis did not have any significant effect.

Table 2. Crude and adjusted analysis of clinical variables affecting mortality and morbidity among coronary artery bypass graft (CABG) and CABG + coronary endarterectomy (CE) patients using the Cox proportional hazard model

| Variable     | HR (95% CI) | P     |
|--------------|-------------|-------|
| CK-MB        |             |       |
| Crude mode   | 0.86 (0.69-0.99) | 0.045 |
| Adjusted     | 0.83 (0.69-1.00) | 0.054 |
| Troponin     |             |       |
| Crude mode   | 1.03 (0.67-1.40) | 0.850 |
| Adjusted     | 0.96 (0.70-1.48) | 0.850 |

Data were adjusted for age, sex, diabetes, hypertension (HTN), hyperlipidemia, smoking, family history, body mass index (BMI), left main disease (LMD), and ejection fraction (EF).

HR: Hazard ratio; CI: Confidence interval; CK-MB: Creatine kinase-myocardial band.
Discussion

The current study evaluated association of cardiac enzymes with morbidity and mortality of patients undergoing CE surgery. We found that there was not a significant association between troponin and CK-MB with morbidity of patients undergoing OPCABG and CE; however, CK-MB had a protective effect in crude model.

Previous study reported that increase in cardiac enzyme release was associated with higher mortality, but our study demonstrated that there was an independent association between cardiac enzyme release and death.

It has been reported in previous study that CK-MB is a sensitive enzyme after surgery for predicting complication. Ramsay et al. reported that increased postoperative peak CK-MB level was a stronger predictor of adverse outcomes. Klatt et al. and Costa et al. found that CK-MB release 5 times or more was associated with an increased risk of mortality at 6 months and one year, respectively. The work by Brener et al. implied that only patients with large cardiac enzyme release (> 10 times) had an association with increased mortality. Abid et al. found that increased cardiac enzyme release increased mortality post-CABG.

Newall et al. reported that release of cardiac enzymes following CAGB was related to one-year all-cause mortality. Domanski et al. reported that increase of CK-MB or troponin levels had an independent relationship with increasing risk of mortality. In our study, there was no significant difference between the groups in changes of cardiac enzyme levels and mortality.

To the best of our knowledge, this is the first study to show that there is not a relationship between cardiac enzyme and survival in CE patients. The strength of our study was that all the surgeries were performed with off-pump technique. This technique has good postoperative outcomes, so that myocyte damage is little and the cardiac enzyme release is low. The limitations of the current study were retrospective design and lack of assessment of other biomarkers such as LDH for evaluation of the degree of postoperative myocardial injury after surgery. A single measurement of CK-MB after surgery added independent prognostic information to established clinical risk factors. Further studies are needed to determine whether patients with high postoperative CK-MB release may benefit from specific medical management.

Conclusion

The results of the current study showed that there was no association between CK-MB and troponin and mortality in patients undergoing CABG. It seems that these biomarkers are not valuable criteria for prediction of death.

Acknowledgments

The authors appreciate the experts of Research Development Center of Imam Ali Hospital and Ayatollah Taleghani Hospital in Kermanshah.

Conflict of Interests

Authors have no conflict of interests.

Authors’ Contribution

AH, FS, AA, and SE contributed to the development of the original idea and the protocol, abstracted and analyzed the data, and prepared the manuscript.

References

1. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J 2004; 148(1): 7-15.
2. Alrashidhan M, Albatain M, Obied H, Allassal M, Albaradai A, Alghofaili F. Does coronary endarterectomy increase early mortality and morbidity compared with coronary artery bypass surgery alone-single centre experience. Int J Clin Med 2014; 5(5): 197-205.
3. Abid AR, Farogh A, Naqshband MS, Akhtar RP, Khan JS. Hospital outcome of coronary artery bypass grafting and coronary endarterectomy. Asian Cardiovasc Thorac Ann 2009; 17(1): 59-63.
4. Hussain I, Ghaffar A, Shalbaz A, Sami W, Muhammad A, Seher N, et al. In hospital outcome of patients undergoing coronary endarterectomy: Comparison between off-pump vs on pump CABG. J Ayub Med Coll Abbottabad 2008; 20(1): 31-7.
5. Marzban M, Karimi A, Ahmadi H, Davoodi S, Abbasi K, Movahedi N, et al. Early outcomes of double-vessel coronary endarterectomy in comparison with single-vessel coronary endarterectomy. Tex Heart Inst J 2008; 35(2): 119-24.
6. Schwann TA, Zacharias A, Riordan CJ, Durham SJ, Shah AS, Habib RH. Survival and graft patency after coronary artery bypass grafting with coronary endarterectomy: Role of arterial versus vein conduits. Ann Thorac Surg 2007; 84(1): 25-31.
7. Lehrke S, Steen H, Sievers HH, Peters H, Opitz A, Muller-Bardorff M, et al. Cardiac troponin T for prediction of short- and long-term morbidity and mortality of patients undergoing coronary artery disease treatment. Ann Thorac Surg 2005; 80(1): 262-7.
mortality after elective open heart surgery. Clin Chem 2004; 50(9): 1560-7.
8. Soylu E, Harling L, Ashrafian H, Casula R, Kokotsakis J, Athanasiou T. Adjunct coronary endarterectomy increases myocardial infarction and early mortality after coronary artery bypass grafting: A meta-analysis. Interact Cardiovasc Thorac Surg 2014; 19(3): 462-73.
9. Neshr N, Alghamdi AA, Singh SK, Sever JY, Christakis GT, Goldman BS, et al. Troponin after cardiac surgery: A predictor or a phenomenon? Ann Thorac Surg 2008; 85(4): 1348-54.
10. Croal BL, Hillis GS, Gibson PH, Fazal MT, El-Shafei H, Gibson G, et al. Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. Circulation 2006; 114(14): 1468-75.
11. Ramsay J, Sherman S, Fitch J, Finnegan P, Todaro T, Filloon T, et al. Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves. J Thorac Cardiovasc Surg 2005; 129(2): 300-6.
12. Klatte K, Chaitman BR, Theroux P, Gavard JA, Stocke K, Boyce S, et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: Results from the GUARDIAN trial. J Am Coll Cardiol 2001; 38(4): 1070-7.
13. Greenson N, Macoviak J, Krishnaswamy P, Morrissey R, James C, Clopton P, et al. Usefulness of cardiac troponin I in patients undergoing open heart surgery. Am Heart J 2001; 141(3): 447-55.
14. Fellahi JL, Gue X, Richomme X, Monier E, Guillou L, Riou B. Short- and long-term prognostic value of postoperative cardiac troponin I concentration in patients undergoing coronary artery bypass grafting. Anesthesiology 2003; 99(2): 270-4.
15. Burtis CA, Bruns DE. Tietz fundamentals of clinical chemistry and diagnostic molecular diagnostics - E-Book. Philadelphia, PA: Elsevier Health Sciences; 2014.
16. Domanski MJ, Mahaffey K, Hasselblad V, Brener SJ, Smith PK, Hillis G, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA 2011; 305(6): 585-91.
17. Soraas CL, Friis C, Engebretsen KV, Sandvik L, Kjeldsen SE, Tonnessen T. Troponin T is a better predictor than creatine kinase-MB of long-term mortality after coronary artery bypass graft surgery. Am Heart J 2012; 164(5): 779-85.
18. Sabzi F, Asadmobini A, Ghasemi F. In-hospital outcome of patients undergoing off-pump coronary artery bypass graft with and without coronary endarterectomy. Res Cardiovasc Med 2017; 6(2): e38872.
19. Sabzi F, Asadmobini A, Rezaei M. Comparing short and long term survival of patients undergoing off pump coronary artery bypass graft with and without coronary endarterectomy. Indian Heart J 2017; 69(5): 646-50.
20. Newall N, Oo AY, Palmer ND, Grayson AD, Hine TJ, Stables RH, et al. Intermediate and high perioperative cardiac enzyme release following isolated coronary artery bypass surgery are independently associated with higher one-year mortality. J Cardiothorac Surg 2006; 1: 20.
21. Costa MA, Carere RG, Lichtenstein SV, Foley DP, de Valk V, Lindenboom W, et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 2001; 104(22): 2689-93.
22. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002; 40(11): 1961-7.
23. Chowdhury UK, Malik V, Yadav R, Seth S, Ramakrishnan L, Kalaivani M, et al. Myocardial injury in coronary artery bypass grafting: On-pump versus off-pump comparison by measuring high-sensitivity C-reactive protein, cardiac troponin I, heart-type fatty acid-binding protein, creatine kinase-MB, and myoglobin release. J Thorac Cardiovasc Surg 2008; 135(5): 1110-9.